First, the expressions of BRCA1 and -2 genes in a tumor can be suppressed by hypermethylation of the gene promoter [28], or somatic mutations and large chromosomal rearrangements can be found in these genes [29], although the impact of these changes on PARP inhibitors and platinum sensitivity remains unclear. This evidence concerns the gene BRCA1 and neoplasm.